# RESOLUTE ONYX China RCT Study

Study · id `cardio:ct-nct03466151` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03466151](<https://clinicaltrials.gov/study/NCT03466151>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03466151

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 550 participants.

## Technical summary

Registry record NCT03466151. Randomized; no masking; primary purpose treatment. Start 2018-04-12 (actual); primary completion 2021-02-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 550 participants (enrolled count; ClinicalTrials.gov record NCT03466151, source copy `cardio:ctgov-nct03466151-2026-10-21`, retrieved 2026-10-26)
- Started: 2018-04-12 (actual) (ClinicalTrials.gov record NCT03466151, source copy `cardio:ctgov-nct03466151-2026-10-21`, retrieved 2026-10-26)
- Primary completion: 2021-02-12 (actual) (ClinicalTrials.gov record NCT03466151, source copy `cardio:ctgov-nct03466151-2026-10-21`, retrieved 2026-10-26)
- Completion: 2025-05-21 (actual) (ClinicalTrials.gov record NCT03466151, source copy `cardio:ctgov-nct03466151-2026-10-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03466151, source copy `cardio:ctgov-nct03466151-2026-10-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03466151-2026-10-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: RESOLUTE ONYX China RCT Study
- Condition: Ischemic Heart Disease
- Condition: Stenotic Coronary Lesion
- Condition: Cardiovascular Diseases
- Condition: Arteriosclerosis
- Condition: Coronary Artery Disease
- Intervention (Device): Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
- Intervention (Device): Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
- Lead sponsor: Medtronic Vascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Medtronic Vascular (`cardio:org-medtronic-vascular`)

## Provenance

Content hash: 13aa7609b1535dea4b6cb25867e0d35b3e09da0274aa1707b8118ff59621c6f8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
